Literature DB >> 23594271

Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Sarah E Poplawski1, Jack H Lai, Youhua Li, Zhiping Jin, Yuxin Liu, Wengen Wu, Yong Wu, Yuhong Zhou, James L Sudmeier, David G Sanford, William W Bachovchin.   

Abstract

Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-d-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594271      PMCID: PMC4059180          DOI: 10.1021/jm400351a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

1.  Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.

Authors:  J E Park; M C Lenter; R N Zimmermann; P Garin-Chesa; L J Old; W J Rettig
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues.

Authors:  T Yoshimoto; M Fischl; R C Orlowski; R Walter
Journal:  J Biol Chem       Date:  1978-05-25       Impact factor: 5.157

4.  Distribution of prolyl endopeptidase activities in rat and human brain.

Authors:  Jon Irazusta; Gorka Larrinaga; Javier González-Maeso; Javier Gil; J Javier Meana; Luis Casis
Journal:  Neurochem Int       Date:  2002-04       Impact factor: 3.921

5.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Authors:  Andrew M Scott; Greg Wiseman; Sydney Welt; Alex Adjei; Fook-Thean Lee; Wendie Hopkins; Chaitan R Divgi; Lorelei H Hanson; Paul Mitchell; Denise N Gansen; Steven M Larson; James N Ingle; Eric W Hoffman; Paul Tanswell; Gerd Ritter; Leonard S Cohen; Peter Bette; Lisa Arvay; Andree Amelsberg; Dan Vlock; Wolfgang J Rettig; Lloyd J Old
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

6.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

Authors:  R Mentlein; B Gallwitz; W E Schmidt
Journal:  Eur J Biochem       Date:  1993-06-15

7.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

Authors:  W J Rettig; P Garin-Chesa; J H Healey; S L Su; H L Ozer; M Schwab; A P Albino; L J Old
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

8.  PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.

Authors:  Sharlene Adams; Glenn T Miller; Michael I Jesson; Takeshi Watanabe; Barry Jones; Barbara P Wallner
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 9.  Sitagliptin: a novel drug for the treatment of type 2 diabetes.

Authors:  Mary Choy; Sum Lam
Journal:  Cardiol Rev       Date:  2007 Sep-Oct       Impact factor: 2.644

10.  Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.

Authors:  Jonathan D Cheng; Roland L Dunbrack; Matthildi Valianou; André Rogatko; R Katherine Alpaugh; Louis M Weiner
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  26 in total

1.  Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

Authors:  Minfeng Chen; Xueping Lei; Changzheng Shi; Maohua Huang; Xiaobo Li; Baojian Wu; Zhengqiu Li; Weili Han; Bin Du; Jianyang Hu; Qiulin Nie; Weiqian Mai; Nan Ma; Nanhui Xu; Xinyi Zhang; Chunlin Fan; Aihua Hong; Minghan Xia; Liangping Luo; Ande Ma; Hongsheng Li; Qiang Yu; Heru Chen; Dongmei Zhang; Wencai Ye
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

Review 2.  Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts.

Authors:  Yali Han; Yanwen Zhang; Tanghong Jia; Yuping Sun
Journal:  Tumour Biol       Date:  2015-02-15

Review 3.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

4.  Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

Authors:  An De Decker; Gwendolyn Vliegen; Dries Van Rompaey; Anke Peeraer; An Bracke; Line Verckist; Koen Jansen; Ruth Geiss-Friedlander; Koen Augustyns; Hans De Winter; Ingrid De Meester; Anne-Marie Lambeir; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2019-07-09       Impact factor: 4.345

Review 5.  Importance of Fibrosis in the Pathogenesis of Uterine Leiomyoma and the Promising Anti-fibrotic Effects of Dipeptidyl Peptidase-4 and Fibroblast Activation Protein Inhibitors in the Treatment of Uterine Leiomyoma.

Authors:  Anusha Shreenidhi Bhat; Ningthoujam Anirudh Singh; Emdormi Rymbai; Swapna Birendra; Saravanan Jayaram; Divakar Selvaraj
Journal:  Reprod Sci       Date:  2022-08-15       Impact factor: 2.924

6.  Inhibition of Dpp8/9 Activates the Nlrp1b Inflammasome.

Authors:  Marian C Okondo; Sahana D Rao; Cornelius Y Taabazuing; Ashley J Chui; Sarah E Poplawski; Darren C Johnson; Daniel A Bachovchin
Journal:  Cell Chem Biol       Date:  2018-01-27       Impact factor: 8.116

7.  Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.

Authors:  Xiao-Ping Chai; Guang-Long Sun; Yan-Fen Fang; Li-Hong Hu; Xuan Liu; Xiong-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

8.  DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis.

Authors:  Marian C Okondo; Darren C Johnson; Ramya Sridharan; Eun Bin Go; Ashley J Chui; Mitchell S Wang; Sarah E Poplawski; Wengen Wu; Yuxin Liu; Jack H Lai; David G Sanford; Michael O Arciprete; Todd R Golub; William W Bachovchin; Daniel A Bachovchin
Journal:  Nat Chem Biol       Date:  2016-11-07       Impact factor: 15.040

9.  Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics.

Authors:  Hui Emma Zhang; Elizabeth J Hamson; Maria Magdalena Koczorowska; Stefan Tholen; Sumaiya Chowdhury; Charles G Bailey; Angelina J Lay; Stephen M Twigg; Quintin Lee; Ben Roediger; Martin L Biniossek; Matthew B O'Rourke; Geoffrey W McCaughan; Fiona M Keane; Oliver Schilling; Mark D Gorrell
Journal:  Mol Cell Proteomics       Date:  2018-09-26       Impact factor: 5.911

10.  A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).

Authors:  James M Kelly; Thomas M Jeitner; Shashikanth Ponnala; Clarence Williams; Anastasia Nikolopoulou; Stephen G DiMagno; John W Babich
Journal:  Mol Imaging Biol       Date:  2021-03-15       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.